Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis

Chandana Thorat, Kui Xu, Scott N. Freeman, Renan A. Bonnel, Francesca Joseph, M. Ian Phillips and Menfo A. Imoisili
Pediatrics March 2012, 129 (3) 516-521; DOI: https://doi.org/10.1542/peds.2011-1798
Chandana Thorat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kui Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott N. Freeman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renan A. Bonnel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Joseph
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Ian Phillips
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Menfo A. Imoisili
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Abstract

OBJECTIVES: The 1983 US Orphan Drug Act (ODA) provided incentives to stimulate treatment product development for patients with rare disease. This article highlights a decade of ODA contributions to this goal for children with RDs.

METHODS: An internal US Food and Drug Administration database was the information source for orphan designations, marketing approvals, and prevalence numbers for 2000 to 2009. Product categorization was based on the disease age of onset for which they received designation. Category 1 products were for diseases with onset exclusively in Childhood; Category 2 products were for diseases with onset at any age; and Category 3 products were for diseases with adult onset only. Disease prevalence distributions were analyzed by using population intervals of 20 000.

RESULTS: From 2000 to 2009, 1138 orphan drugs were designated and 148 received marketing approval, of which 38 (26%) were for pediatric diseases. The proportion of approvals for pediatric products increased from 17.5% (10 of 57) in the first half of the decade, to 30.8% (28 of 91) in the second. More products received designation and marketing approval for pediatric diseases with prevalence numbers fewer than 20 000 than for any other prevalence subgroup. The median disease prevalence for all pediatric orphan designations that received marketing approval was 8972. Among the pediatric orphan drug approvals categorized by therapeutic class, the endocrine/metabolic drugs had the largest representation (39%).

CONCLUSIONS: The ODA incentives have led to increased product availability for RDs overall, with an increasing number of marketing approvals for children this past decade.

KEY WORDS
  • orphan drugs
  • rare diseases
  • Orphan Drug Act
  • pediatrics
  • Abbreviations:
    FDA —
    US Food and Drug Administration
    ODA —
    Orphan Drug Act
    RD —
    rare disease
    • Accepted October 27, 2011.
    • Copyright © 2012 by the American Academy of Pediatrics

    Individual Login

    Log in
    You will be redirected to aap.org to login or to create your account.

    Institutional Login

    via Institution

    You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

    Log in through your institution

    If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

    Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00

    Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

    Offer Reprints

    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 129, Issue 3
    1 Mar 2012
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
    Chandana Thorat, Kui Xu, Scott N. Freeman, Renan A. Bonnel, Francesca Joseph, M. Ian Phillips, Menfo A. Imoisili
    Pediatrics Mar 2012, 129 (3) 516-521; DOI: 10.1542/peds.2011-1798

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
    Chandana Thorat, Kui Xu, Scott N. Freeman, Renan A. Bonnel, Francesca Joseph, M. Ian Phillips, Menfo A. Imoisili
    Pediatrics Mar 2012, 129 (3) 516-521; DOI: 10.1542/peds.2011-1798
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Abstract
      • METHODS
      • RESULTS
      • Discussion
      • CONCLUSIONS
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • Comments

    Related Articles

    • No related articles found.
    • PubMed
    • Google Scholar

    Cited By...

    • Pediatric Orphan Drug Indications: 2010-2018
    • Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations
    • Tissue engineering of blood vessels in cardiovascular disease: moving towards clinical translation
    • IOM Review of FDA-Approved Biologics Labeled or Studied for Pediatric Use
    • Google Scholar

    More in this TOC Section

    • Predictive Models of Neurodevelopmental Outcomes After Neonatal Hypoxic-Ischemic Encephalopathy
    • A Technology-Assisted Language Intervention for Children Who Are Deaf or Hard of Hearing: A Randomized Clinical Trial
    • Standard Versus Long Peripheral Catheters for Multiday IV Therapy: A Randomized Controlled Trial
    Show more Article

    Similar Articles

    Subjects

    • Pharmacology
      • Pharmacology
    • Medical Education
      • Medical Education
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics